Advanced Diagnostic Testing That Reveals What Standard Tests Miss
The Flow 7 Advanced Testing System is a 7-minute, FDA-cleared, non-invasive diagnostic tool that assesses autonomic nervous system function, vascular health, and peripheral circulation — detecting conditions years before symptoms appear.
Covered by Medicare and most commercial insurance. Ideal for Endocrinology, Cardiology, Primary Care, Podiatry, and Neurology practices.
7–15 min
Complete assessment
FDA
Cleared device
$200–$300
Medicare reimbursement
3-in-1
Combined test panel
A 3-in-1 Diagnostic Panel — Completed in 7–15 Minutes
The Flow 7 system combines three powerful non-invasive tests into a single in-office session, typically completing in 7–15 minutes and delivering a comprehensive picture of a patient's autonomic and vascular health before they leave the exam room.
ANS / Cardiac Autonomic Assessment
Cardiovagal Innervation Testing
Measures heart rate variability and autonomic nervous system balance — identifying cardiac autonomic neuropathy (CAN), a condition present in up to 60% of patients with longstanding diabetes and a 5-fold increase in mortality risk when undetected.
Sudomotor / Sweat Function Test
Small Fiber Neuropathy Screening
Evaluates sweat gland function to reveal autonomic nerve damage — often the earliest detectable sign of diabetic peripheral neuropathy, identifiable years before pain or sensory loss begins.
ABI — Ankle-Brachial Index
Peripheral Arterial Disease Screening
Measures blood flow and pressure ratios between the arms and legs to identify peripheral artery disease (PAD), arterial blockage, and vascular circulation deficits — critical for diabetic and podiatric patients.
7–15 Minutes
Total testing time
FDA-Cleared
Professional-grade accuracy
Medicare Covered
Plus most commercial plans
No Upfront Cost
Flat per-use rate model
Built for Five Key Medical Specialties
The Flow 7 system addresses the specific diagnostic needs of each specialty — enabling earlier detection, better treatment decisions, and improved patient outcomes.
Endocrinology
Diabetes & Metabolic DisordersFor endocrinologists, the Flow 7 system is a game-changing early detection tool. Diabetic autonomic neuropathy (DAN) affects up to 60% of patients with longstanding diabetes — yet it is clinically silent until advanced stages. The system detects insulin resistance 8–10 years before diabetic symptoms emerge and identifies cardiac autonomic neuropathy that increases mortality risk 5-fold.
Cardiology
Cardiovascular Risk AssessmentCardiac autonomic imbalance — particularly elevated sympathetic tone — can precede arrhythmia, hypertension, and endothelial dysfunction. The Flow 7 system detects vascular dysfunction and arterial stiffness years before plaque becomes visible on imaging, giving cardiologists an objective, quantitative window into early disease progression that complements existing stress testing.
Primary Care
Population Health & PreventionPrimary care is the frontline of prevention — and the Flow 7 system was designed to seamlessly integrate into your practice workflow. A medical assistant or technician administers the 7-minute test before the physician encounter. Results are ready for review during the visit, enabling same-day clinical decisions. The system also facilitates coordinated care referrals with specialists by providing shared, objective data.
Podiatry
Diabetic Foot & Vascular CarePodiatrists treating diabetic patients face the constant challenge of quantifying vascular and nerve compromise before tissue damage becomes irreversible. The Flow 7's ABI measurement and sudomotor nerve testing instantly distinguishes between vascular and neurological peripheral neuropathy — guiding treatment protocols, supporting wound care decisions, and providing objective documentation for medical necessity under Medicare Q-modifier requirements.
Neurology
Autonomic & Peripheral NeuropathyFor neurologists, the Flow 7 provides a fast, quantitative assessment of the autonomic nervous system that complements nerve conduction studies. It measures small fiber nerve function via sudomotor testing — providing early detection of autonomic neuropathy that is otherwise only identifiable through extensive and costly workups. The system provides color-coded, auto-interpreted results ready for physician review before the patient leaves.
Who Qualifies for Flow 7 Testing?
A wide range of patient populations meet medical necessity criteria for Flow 7 testing. The following conditions and risk factors are recognized by Medicare and most commercial payers as qualifying indications.
Qualifying Diagnoses
Risk Factors That Support Medical Necessity
Billable CPT Codes
Medicare reimbursement: $200–$300 per testing session. Coverage verified with most commercial payers.
Covered by Medicare & Most Commercial Insurance
Flow 7 testing is reimbursed under established Medicare CPT codes. The flat per-use pricing model means no capital investment or equipment purchase is required. Most practices see positive returns from the very first month of integration.
What This Means for Your Patients
The Flow 7 Advanced Testing System delivers a clinical experience that is fast, comfortable, and genuinely life-changing — giving patients answers their standard testing simply cannot provide.
Results in 7–15 Minutes
Patients complete the full 3-panel assessment in as little as 7 minutes, typically 15 minutes or less. No special preparation. No hospital visit. Results are ready before they leave the office.
Completely Non-Invasive
No needles, no radiation, no discomfort. Blood pressure cuffs, sensor pads, and a finger probe are the only contact points — appropriate for patients of all ages and risk levels.
Early Detection Saves Lives
Detecting autonomic neuropathy, PAD, or insulin resistance years earlier enables lifestyle changes and treatment interventions that can prevent heart attacks, amputations, and kidney failure.
Plain-Language Reports
Color-coded results with automatic interpretation are reviewed with the patient during the visit — no waiting days or weeks for confusing lab results to arrive.
Coordinated Care
Results are shared digitally between primary care and specialty providers, enabling coordinated treatment decisions and reducing redundant testing across the care team.
Covered by Insurance
Medicare and most major commercial insurance plans cover Flow 7 testing when medical necessity criteria are met — minimizing out-of-pocket costs for patients.
Detect Disease Years Earlier
Identified before blood glucose levels become abnormal, enabling lifestyle intervention at its most effective window.
Present in up to 60% of longstanding diabetics — virtually undetectable without ANS testing, yet carrying a 5x mortality risk increase.
ABI below 0.9 indicates significant arterial obstruction. Earlier detection preserves limb viability and prevents emergency interventions.
Arterial stiffness and endothelial dysfunction are detectable years before stroke, heart attack, or cardiovascular events occur.
Clinical Validation
CMRS: Cardio Metabolic Risk Score
The Flow 7 system calculates a comprehensive Cardio Metabolic Risk Score (CMRS) based on all recorded parameters — validated by the University of Miami as a reliable marker for pre-diabetes, diabetes, and cardiovascular disease risk.
Reference: Mendez AJ, Crandall JP, et al. "Cardiometabolic Risk Score and Autonomic Function as Predictors of Metabolic Disease." University of Miami Miller School of Medicine. Published in Diabetes Care, validating CMRS as an early marker for pre-diabetes and cardiovascular risk.
7–15 min
Test time
3-in-1
Panel tests
1 score
Unified risk
See What a Flow 7 Report Looks Like
Each 7–15 minute session produces a comprehensive multi-page report covering lifestyle, homeostatic, microvascular, macrovascular, and autonomic assessments — with a unified Cardiometabolic Risk Score and plain-language clinical comments ready for physician review.
Lifestyle Assessment
Stress response markers, body composition, ANS balance (Total Power, HF, LF/HF Ratio, SDANN), BMI, and a personalized weight/calorie plan.
- Total Power (ANS activity)
- LF/HF Ratio (autonomic balance)
- Body Fat Mass & BMI
- Calorie range & target weight
Homeostatic Assessment
PTG spectral analysis markers for insulin resistance, endothelial homeostasis, and autonomic homeostasis — plus vital signs and cardiac output indices.
- PTG Total Power (insulin resistance)
- PTG Index (endothelial homeostasis)
- Stress Index (inflammation marker)
- Cardiac Index & Stroke Volume
Microvascular & Autonomic
Sudomotor (sweat gland) small fiber nerve assessment, nitric oxide microcirculation markers, and cardiovagal reflex test (CARTs) results.
- Nitric Oxide Peak (microcirculation)
- Sweat Peak (small fiber neuropathy)
- Valsalva Ratio (baroreceptor)
- E/I Ratio (cardiovagal innervation)
Macrovascular Assessment
Arterial stiffness markers, brachial blood pressure, ankle-brachial index (ABI), and pulse wave velocity for peripheral arterial disease screening.
- Reflection Index (arterial stiffness)
- Central Aortic Systolic Pressure
- Left & Right ABI (PAD screening)
- ba Pulse Wave Velocity
Unified Cardiometabolic Risk Score
The final report page delivers a single Cardiometabolic Risk Score (CMRS) — a composite percentage validated by the University of Miami — alongside four sub-scores for Lifestyle, Homeostasis, Macrovascular, and ANS function. Each score includes plain-language clinical comments and suggested next steps, making it immediately actionable for the physician.
CMRS
35%
Moderate Risk
Overall cardiometabolic risk
Lifestyle
5%
Abnormal
ANS & body composition
Homeostasis
6%
Abnormal
Endothelial & autonomic
ANS
6%
Abnormal
Microvascular & small fiber
Sample report shown for illustration purposes. Patient data is de-identified.
Ready to Bring Flow 7 Testing to Your Practice?
Cardio Metabolic Solutions LLC works with Endocrinology, Cardiology, Primary Care, Podiatry, and Neurology practices to implement the Flow 7 Advanced Testing System with no upfront capital investment. Contact us today to learn more.
Contact Us Directly
Tom Carlyle, D.C.
V.P. of Services
Serving healthcare practices nationwide. Response within 1 business day.
Request More Information
Fill out the form below and a specialist will follow up within 1 business day.